Glaxo dives on patents setback in US court

GlaxoSmithKline, Europe's biggest drug maker, vowed yesterday to defend patents on its biggest-selling antibiotic after it lost a court battle and saw £8.5bn wiped off its market value.

Three drug manufacturing companies have mounted a successful legal campaign to overturn half a dozen US patents that protect the way GSK makes Augmentin, a multi-purpose antibiotic that had sales of almost £4m a day last year. Augmentin is one of the company's most profitable drugs.

GSK admitted that if its rivals were to launch cheap, generic versions of the drug in the next few weeks, it would have to issue a profit warning. Its shares plunged 140p to 1471p, taking them to their lowest since the company was created from the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

The three victorious companies yesterday put off decisions over whether to launch their cheap versions of the drug. GSK vowed to appeal the decision and threatened to sue them for loss of earnings if the patents were upheld on appeal after the generic versions had been launched.

Jean-Pierre Garnier, the chief executive of GSK, warned the companies they would be taking a big gamble.

"This would be a big risk for them, and if we were to ultimately win, we would be entitled to full compensation for loss of profits, which would of course be a significant sum. They will only be making a fraction of the profit we would, so they will be required to repay profits they haven't made."

Only one of the three, Geneva Pharmaceuticals, has so far received approval to sell their generic version in the US. Geneva is a division of Novartis, the Swiss drugs giant, and analysts said the chances of Novartis risking launching its product early were "50-50".

A spokesman for Geneva said the company has not made a decision, but was "anxious to get the product into the hands of patients as soon as possible".

Sources said Geneva is likely to make a decision in about a month, when GSK files its appeal.

Although Augmentin accounts for just 5 per cent of GSK's sales, it emerged yesterday that the drug contributes a significantly higher proportion of its profits.

GSK said that, in a worst case scenario, its earnings growth would be 10 per cent this year, not the "mid-teens" currently predicted. Earnings growth next year would fall from the low-teens to high single digits.

City observers said that this would increase the chances of GSK seeking a big acquisition to plug the earnings gap. It has long been linked with the troubled US firm Bristol-Myers Squibb.

The Virginia judge's ruling, late on Thursday, came as a surprise. He threw out three patents, expiring in June, July and December of this year, having previously upheld the December patent when it was challenged on different grounds a few months ago.

Last year he threw out patents which GSK claims extends protection for Augmentin to 2018. These will be appealed at the same time as the patents in this week's case. Mr Garnier said the appeal would most likely take between 12 and 18 months, but might be over within eight.

He said he would stop promoting regular Augmentin if generic rivals launched this summer, switching the US salesforce to marketing the new version of the drug, Augmentin ER, a version for children which already accounts for 13 per cent of Augmentin prescriptions. Augmentin XR, an improved version for adults, is due to be launched in December, but analysts said the existence of generic competition would hit GSK's chances of a successful launch.

Start your day with The Independent, sign up for daily news emails
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Retirement Coordinator - Financial Services

Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...

Recruitment Genius: Annuities / Pensions Administrator

Negotiable: Recruitment Genius: You will be the first point of contact for all...

Ashdown Group: HR, Payroll & Benefits Officer - Altrincham - up to £24,000.

£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...

Ashdown Group: Learning and Development Programme Manager

£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...

Day In a Page

The saffron censorship that governs India: Why national pride and religious sentiment trump freedom of expression

The saffron censorship that governs India

Zareer Masani reveals why national pride and religious sentiment trump freedom of expression
Prince Charles' 'black spider' letters to be published 'within weeks'

Prince Charles' 'black spider' letters to be published 'within weeks'

Supreme Court rules Dominic Grieve's ministerial veto was invalid
Distressed Zayn Malik fans are cutting themselves - how did fandom get so dark?

How did fandom get so dark?

Grief over Zayn Malik's exit from One Direction seemed amusing until stories of mass 'cutting' emerged. Experts tell Gillian Orr the distress is real, and the girls need support
The galaxy collisions that shed light on unseen parallel Universe

The cosmic collisions that have shed light on unseen parallel Universe

Dark matter study gives scientists insight into mystery of space
The Swedes are adding a gender-neutral pronoun to their dictionary

Swedes introduce gender-neutral pronoun

Why, asks Simon Usborne, must English still struggle awkwardly with the likes of 's/he' and 'they'?
Disney's mega money-making formula: 'Human' remakes of cartoon classics are part of a lucrative, long-term creative plan

Disney's mega money-making formula

'Human' remakes of cartoon classics are part of a lucrative, long-term creative plan
Lobster has gone mainstream with supermarket bargains for £10 or less - but is it any good?

Lobster has gone mainstream

Anthea Gerrie, raised on meaty specimens from the waters around Maine, reveals how to cook up an affordable feast
Easter 2015: 14 best decorations

14 best Easter decorations

Get into the Easter spirit with our pick of accessories, ornaments and tableware
Paul Scholes column: Gareth Bale would be a perfect fit at Manchester United and could turn them into serious title contenders next season

Paul Scholes column

Gareth Bale would be a perfect fit at Manchester United and could turn them into serious title contenders next season
Inside the Kansas greenhouses where Monsanto is 'playing God' with the future of the planet

The future of GM

The greenhouses where Monsanto 'plays God' with the future of the planet
Britain's mild winters could be numbered: why global warming is leaving UK chillier

Britain's mild winters could be numbered

Gulf Stream is slowing down faster than ever, scientists say
Government gives £250,000 to Independent appeal

Government gives £250,000 to Independent appeal

Donation brings total raised by Homeless Veterans campaign to at least £1.25m
Oh dear, the most borrowed book at Bank of England library doesn't inspire confidence

The most borrowed book at Bank of England library? Oh dear

The book's fifth edition is used for Edexcel exams
Cowslips vs honeysuckle: The hunt for the UK’s favourite wildflower

Cowslips vs honeysuckle

It's the hunt for UK’s favourite wildflower
Child abuse scandal: Did a botched blackmail attempt by South African intelligence help Cyril Smith escape justice?

Did a botched blackmail attempt help Cyril Smith escape justice?

A fresh twist reveals the Liberal MP was targeted by the notorious South African intelligence agency Boss